Genetic susceptibility to endometrial cancer risk in PLCO
Principal Investigator
Name
Nicolas Wentzensen MD
Degrees
-
Institution
NCI, DCEG, HREB
Position Title
-
Email
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
2010-0050
Initial CDAS Request Approval
Mar 1, 2010
Title
Genetic susceptibility to endometrial cancer risk in PLCO
Summary
There are currently two major efforts to conduct genome wide associations studies (GWAS) to identify genetic markers of susceptibility for endometrial cancer. Dr. Immaculata DeVivo (Harvard University) was recently funded through NCIs ARRA mechanism to support a primary scan in approximately 2,400 endometrial cases and 2,400 matched controls (Illumina 660K) in the USA (ACS, NHS, EPIC, MEC, Connecticut, California Teachers Cohort, and FHCRC), with replication in US studies participating in the Epidemiology of Endometrial Cancer Consortium (E2C2). Drs. Amanda Spurdle (QIMR, Australia) and Doug Easton (Cambridge University, UK) are leading an independent effort to conduct a primary scan (Illumina 610K) of 700 Australian and 700 British endometrial cancer cases, using available scan data for controls. We have previously agreed to replicate findings in the Polish Endometrial Study (PECS) from both efforts and in the PLCO study from the USA scan. A summary of the studies involved in the two GWAS efforts are described in Supplementary Table 1. Here, we propose to conduct a primary scan using the Illumina 660K platform on 600 endometrial cancer cases from PLCO to collaborate with the NCI-funded study to increase the statistical power of the USA-led GWAS. In addition, we are pledged to later participate in pooling with the ongoing Australian/UK-led GWAS. We have approval and funding from DCEG to run these assays. Cases from PLCO will be compared to existing female controls from previous GWAS studies. The combined contribution of 1030 endometrial cases from PECS and PLCO will increase the size of the US primary scan by 30%, resulting in substantial gain in power, particularly for endometrial cancer cases with both risk factor data and tumor samples. Beyond contributing to GWAS efforts, a GWAS scan of the PLCO cases and controls will allow exploring relationships of common variants with circulating hormone levels currently analyzed in PLCO and will create a highly valuable resource for future studies of genetic susceptibility and endometrial cancer outcomes in PLCO.
Since the time-window for the ARRA-funded GWAS is limited, PLCO leadership recommended an expedited impact analysis and sample selection process for this proposal under the condition that no samples are released from the repository before final approval.
Since the time-window for the ARRA-funded GWAS is limited, PLCO leadership recommended an expedited impact analysis and sample selection process for this proposal under the condition that no samples are released from the repository before final approval.
Aims
We propose to study common genetic variants in relation to endometrial cancer risk in PLCO. This project will create a nested case-control study with extracted DNA from buffy coats/buccal cells in the screened and unscreened arms of PLCO that will also be a resource for future DNA based studies. In addition, we will provide extensive genotyping data for the PLCO endometrial cancer cases that can be used for future studies of genetic susceptibility in relation to various endpoints.
AIM1: Identify and characterize common genetic variants associated with endometrial cancer risk
· To conduct genome-wide scan of PLCO endometrial cancer cases and controls that will augment the current GWAS efforts.
· To contribute data from dense genotyping in PLCO cases and controls to consortial studies that follow up on established susceptibility loci, including fine mapping and associations with tumor characteristics.
· To carry out gene-environment interactions of established loci, to identify novel loci with weak overall effects using novel statistical methods, and to improve our ability to carry out pathway-based
analyses in endometrial cancer in PLCO
AIM2: Explore common genetic variation in relation to endogenous hormone levels
· To explore the relation between SNPs and endogenous hormone levels in endometrial cancer
cases and controls within PLCO.
Collaborators
Louise Brinton (HREB, DCEG)
Arpita Gosh (BB, DCEG)
Patricia Hartge (DCEG)
Stephen Chanock (LTG, DCEG)
Montserrat Garcia-Closas (HREB, DCEG)
Sholom Wacholder (BB, DCEG)
Hannah Yang (HREB, DCEG)
Mark Sherman (HREB, DCEG)
Related Publications
-
Mosaic 13q14 deletions in peripheral leukocytes of non-hematologic cancer cases and healthy controls.
Machiela MJ, Zhou W, Caporaso N, Dean M, Gapstur SM, Goldin L, Stevens VL, Yeager M, Chanock SJ
J. Hum. Genet. 2016 May; Volume 61 (Issue 5): Pages 411-8 PUBMED -
Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types.
Sampson JN, Wheeler WA, Yeager M, Panagiotou O, Wang Z, Berndt SI, Lan Q, Abnet CC, Amundadottir LT, Figueroa JD, Landi MT, Mirabello L, Savage SA, Taylor PR, De Vivo I, McGlynn KA, Purdue MP, Rajaraman P, Adami HO, Ahlbom A, ...show more Albanes D, Amary MF, An SJ, Andersson U, Andriole G, Andrulis IL, Angelucci E, Ansell SM, Arici C, Armstrong BK, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Becker N, Benavente Y, Benhamou S, Berg C, Van Den Berg D, Bernstein L, Bertrand KA, Birmann BM, Black A, Boeing H, Boffetta P, Boutron-Ruault MC, Bracci PM, Brinton L, Brooks-Wilson AR, Bueno-de-Mesquita HB, Burdett L, Buring J, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Carrato A, Carreon T, Carta A, Chan JK, Chang ET, Chang GC, Chang IS, Chang J, Chang-Claude J, Chen CJ, Chen CY, Chen C, Chen CH, Chen C, Chen H, Chen K, Chen KY, Chen KC, Chen Y, Chen YH, Chen YS, Chen YM, Chien LH, Chirlaque MD, Choi JE, Choi YY, Chow WH, Chung CC, Clavel J, Clavel-Chapelon F, Cocco P, Colt JS, Comperat E, Conde L, Connors JM, Conti D, Cortessis VK, Cotterchio M, Cozen W, Crouch S, Crous-Bou M, Cussenot O, Davis FG, Ding T, Diver WR, Dorronsoro M, Dossus L, Duell EJ, Ennas MG, Erickson RL, Feychting M, Flanagan AM, Foretova L, Fraumeni JF, Freedman ND, Beane Freeman LE, Fuchs C, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, García-Closas R, Gascoyne RD, Gastier-Foster J, Gaudet MM, Gaziano JM, Giffen C, Giles GG, Giovannucci E, Glimelius B, Goggins M, Gokgoz N, Goldstein AM, Gorlick R, Gross M, Grubb R, Gu J, Guan P, Gunter M, Guo H, Habermann TM, Haiman CA, Halai D, Hallmans G, Hassan M, Hattinger C, He Q, He X, Helzlsouer K, Henderson B, Henriksson R, Hjalgrim H, Hoffman-Bolton J, Hohensee C, Holford TR, Holly EA, Hong YC, Hoover RN, Horn-Ross PL, Hosain GM, Hosgood HD, Hsiao CF, Hu N, Hu W, Hu Z, Huang MS, Huerta JM, Hung JY, Hutchinson A, Inskip PD, Jackson RD, Jacobs EJ, Jenab M, Jeon HS, Ji BT, Jin G, Jin L, Johansen C, Johnson A, Jung YJ, Kaaks R, Kamineni A, Kane E, Kang CH, Karagas MR, Kelly RS, Khaw KT, Kim C, Kim HN, Kim JH, Kim JS, Kim YH, Kim YT, Kim YC, Kitahara CM, Klein AP, Klein RJ, Kogevinas M, Kohno T, Kolonel LN, Kooperberg C, Kricker A, Krogh V, Kunitoh H, Kurtz RC, Kweon SS, LaCroix A, Lawrence C, Lecanda F, Lee VH, Li D, Li H, Li J, Li YJ, Li Y, Liao LM, Liebow M, Lightfoot T, Lim WY, Lin CC, Lin D, Lindstrom S, Linet MS, Link BK, Liu C, Liu J, Liu L, Ljungberg B, Lloreta J, Di Lollo S, Lu D, Lund E, Malats N, Mannisto S, Le Marchand L, Marina N, Masala G, Mastrangelo G, Matsuo K, Maynadie M, McKay J, McKean-Cowdin R, Melbye M, Melin BS, Michaud DS, Mitsudomi T, Monnereau A, Montalvan R, Moore LE, Mortensen LM, Nieters A, North KE, Novak AJ, Oberg AL, Offit K, Oh IJ, Olson SH, Palli D, Pao W, Park IK, Park JY, Park KH, Patiño-Garcia A, Pavanello S, Peeters PH, Perng RP, Peters U, Petersen GM, Picci P, Pike MC, Porru S, Prescott J, Prokunina-Olsson L, Qian B, Qiao YL, Rais M, Riboli E, Riby J, Risch HA, Rizzato C, Rodabough R, Roman E, Roupret M, Ruder AM, Sanjose Sd, Scelo G, Schned A, Schumacher F, Schwartz K, Schwenn M, Scotlandi K, Seow A, Serra C, Serra M, Sesso HD, Setiawan VW, Severi G, Severson RK, Shanafelt TD, Shen H, Shen W, Shin MH, Shiraishi K, Shu XO, Siddiq A, Sierrasesúmaga L, Sihoe AD, Skibola CF, Smith A, Smith MT, Southey MC, Spinelli JJ, Staines A, Stampfer M, Stern MC, Stevens VL, Stolzenberg-Solomon RS, Su J, Su WC, Sund M, Sung JS, Sung SW, Tan W, Tang W, Tardón A, Thomas D, Thompson CA, Tinker LF, Tirabosco R, Tjønneland A, Travis RC, Trichopoulos D, Tsai FY, Tsai YH, Tucker M, Turner J, Vajdic CM, Vermeulen RC, Villano DJ, Vineis P, Virtamo J, Visvanathan K, Wactawski-Wende J, Wang C, Wang CL, Wang JC, Wang J, Wei F, Weiderpass E, Weiner GJ, Weinstein S, Wentzensen N, White E, Witzig TE, Wolpin BM, Wong MP, Wu C, Wu G, Wu J, Wu T, Wu W, Wu X, Wu YL, Wunder JS, Xiang YB, Xu J, Xu P, Yang PC, Yang TY, Ye Y, Yin Z, Yokota J, Yoon HI, Yu CJ, Yu H, Yu K, Yuan JM, Zelenetz A, Zeleniuch-Jacquotte A, Zhang XC, Zhang Y, Zhao X, Zhao Z, Zheng H, Zheng T, Zheng W, Zhou B, Zhu M, Zucca M, Boca SM, Cerhan JR, Ferri GM, Hartge P, Hsiung CA, Magnani C, Miligi L, Morton LM, Smedby KE, Teras LR, Vijai J, Wang SS, Brennan P, Caporaso NE, Hunter DJ, Kraft P, Rothman N, Silverman DT, Slager SL, Chanock SJ, Chatterjee N
J. Natl. Cancer Inst. 2015 Dec; Volume 107 (Issue 12): Pages djv279 PUBMED